

Supplemental Tables for:
 EFFECTS OF EXERCISE ON CHEMOTHERAPY COMPLETION AND HOSPITALIZATION RATES: THE OPTITRAIN BREAST CANCER TRIAL
 Sara Mijwel et al.

Supplemental Table S1. Participant baseline characteristics among chemotherapy dose completers and non-completers and among hospitalized and non-hospitalized participants.

	Dose reduction (n=48)	No dose reduction (n=158)	p-value*	Hospitalized (n=14)	Not hospitalized (n=192)	p-value*
	Mean±SD	Mean±SD		Mean±SD	Mean±SD	
Age (yrs)	52±11	53±10	0.564	52±9	53±10	0.571
Body mass (kg)	66.7±11.6	68.9±11.9	0.250	69.6±9.1	68.3±12.0	0.696
Body mass index (kg/m ²)	24.5±4.2	25.1±4.3	0.373	24.9±3.3	25.0±4.4	0.973
SED (min/day)	550.34±117.5	536.1±105.3	0.197	563.4±108.6	539.4±108.4	0.433
MVPA (min/day)	67.8±28.7	75.4±33.1	0.173	67.7±38.2	74.2±32.3	0.468
	%	%	p-value†	%	%	p-value†
Married or partnered	50	66.7	0.044	84.6	61.4	0.137
University completed	70.5	64.9	0.495	76.9	65.4	0.549
Postmenopausal women	60.4	58.9	0.848	64.3	58.9	0.690
Comorbidities	36.4	30.3	0.447	61.5	29.6	0.027
Tumor receptor status:			0.418			0.952

Triple negative	20.8	12.0		14.3	14.1	
HER2+, ER+/-	20.8	24.6		14.2	24.5	
HER2-, ER+	58.3	62.0		71.4	60.4	
HER2-, ER-	0.0	1.3		0.0	1.0	
Chemotherapy received at baseline:			0.262			0.040
Taxane/taxane+anthracycline based therapy	66.7	57.6		85.7	57.8	
Anthracycline based therapy	33.3	42.4		14.3	42.2	
G-CSF treatment	89.6	74.7	0.029	92.9	77.1	0.168

SD, standard deviation; SED, sedentary time; MVPA, moderate to vigorous physical activity; G-CSF, granulocyte colony stimulating factor; *One-way ANOVA, †Exact χ^2 test/Fisher's exact test; p-value<0.05 highlighted in bold font